These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 18254490)

  • 1. Effect of omalizumab on patients with chronic urticaria: issues with the determination of autoimmune urticaria.
    Sheikh J
    Ann Allergy Asthma Immunol; 2008 Jan; 100(1):88; author reply 88-9. PubMed ID: 18254490
    [No Abstract]   [Full Text] [Related]  

  • 2. Observations on the mechanism of omalizumab as a steroid-sparing agent in autoimmune or chronic idiopathic urticaria and angioedema.
    Dreyfus DH
    Ann Allergy Asthma Immunol; 2008 Jun; 100(6):624-5. PubMed ID: 18592835
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of chronic autoimmune urticaria with omalizumab.
    Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies.
    Chakravarty SD; Yee AF; Paget SA
    J Allergy Clin Immunol; 2011 Dec; 128(6):1354-5. PubMed ID: 21958584
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of omalizumab on patients with chronic urticaria.
    Spector SL; Tan RA
    Ann Allergy Asthma Immunol; 2007 Aug; 99(2):190-3. PubMed ID: 17718108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic autoimmune urticaria: treatment with omalizumab].
    Máspero JF; Parisi CA; De Gennaro M; Benhabib O; Lampert M
    Arch Argent Pediatr; 2009 Oct; 107(5):452-6. PubMed ID: 19809768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
    Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
    J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of autoimmune activation of basophils in chronic urticaria.
    Kikuchi Y; Kaplan AP
    J Allergy Clin Immunol; 2001 Jun; 107(6):1056-62. PubMed ID: 11398085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of basophil CD203c-upregulating activity as an immunological marker to predict response to treatment with omalizumab in patients with symptomatic chronic urticaria.
    Palacios T; Stillman L; Borish L; Lawrence M
    J Allergy Clin Immunol Pract; 2016; 4(3):529-30. PubMed ID: 26725153
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic autoimmune urticaria.
    Wardhana ; Datau EA
    Acta Med Indones; 2012 Apr; 44(2):165-74. PubMed ID: 22745150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous occurrence of chronic autoimmune urticaria and non-allergic asthma: a common mechanism?
    Tedeschi A; Cottini M; Asero R
    Eur Ann Allergy Clin Immunol; 2009 Apr; 41(2):56-9. PubMed ID: 19585861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basophil FcɛRI expression is linked to time to omalizumab response in chronic spontaneous urticaria.
    Deza G; Bertolín-Colilla M; Sánchez S; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol; 2018 Jun; 141(6):2313-2316.e1. PubMed ID: 29518420
    [No Abstract]   [Full Text] [Related]  

  • 13. Omalizumab also successful in chronic urticaria.
    Spector SL; Tan RA
    J Allergy Clin Immunol; 2008 Mar; 121(3):784; author reply 784-5. PubMed ID: 18328900
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy of omalizumab in delayed pressure urticaria: a case report.
    Bindslev-Jensen C; Skov PS
    Allergy; 2010 Jan; 65(1):138-9. PubMed ID: 19804440
    [No Abstract]   [Full Text] [Related]  

  • 15. Failure of omalizumab in cholinergic urticaria.
    Sabroe RA
    Clin Exp Dermatol; 2010 Jun; 35(4):e127-9. PubMed ID: 19925484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic idiopathic urticaria with functional autoantibodies: 12 years on.
    Sabroe RA; Greaves MW
    Br J Dermatol; 2006 May; 154(5):813-9. PubMed ID: 16634880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab.
    Magerl M; Staubach P; Altrichter S; Ardelean E; Krause K; Metz M; Weller K; Maurer M
    J Allergy Clin Immunol; 2010 Sep; 126(3):665-6. PubMed ID: 20673981
    [No Abstract]   [Full Text] [Related]  

  • 18. Omalizumab therapy in three patients with chronic autoimmune urticaria.
    Al-Ahmad M
    Ann Saudi Med; 2010; 30(6):478-81. PubMed ID: 20864790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab as a therapeutic alternative for chronic urticaria.
    Callejas-Rubio JL; Sánchez-Cano D; Lara MA; Ortego-Centeno N
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):556. PubMed ID: 19055216
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
    Kaplan AP; Giménez-Arnau AM; Saini SS
    Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.